NCT00838227

Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder

Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder: A Pilot Study

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Manhattan Psychiatric Center · Academic / Other
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

This is an open label 8-week trial of modafinil up to 400 mg daily added to a stable antipsychotic regimen to evaluate the effect modafinil on cognition, sedation, and weight in patients with chronic schizophrenia. We hypothesize that modafinil, a wake-promoting agent, will lead to improved cognition, increased wakefulness, and decreased weight in patients with schizophrenia who are on stable antipsychotic regimens

Detailed description

This study was withdrawn due to no source of funding to implement the study. No participants were enrolled for this study.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	modafinil	Modafinil up to 400 mg daily will be added to a stable antipsychotic regimen

Timeline

• Start date: 2008-02-01
• Primary completion: 2012-01-01
• Completion: 2012-06-01
• First posted: 2009-02-06
• Last updated: 2020-10-14